ScopeSys: Funding, Investors & Team (Nov 2026)
ScopeSys is a commercial-stage developer of disruptive technologies for single-molecule imaging.
ScopeSys has raised $1.1M across 1 funding round on record, the most recent a Seed of $1.1M announced in Aug 2026.
That round is below the $2.2M median round size for Canada companies tracked on FundedIQ over the last two years.
ScopeSys Company Profile and Key Stats
Latest funding round on record: Aug 2026.
ScopeSys Funding Rounds
ScopeSys Investors
ScopeSys Founders and Leadership Team
Contact details for the ScopeSys team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →ScopeSys Funding in Context
ScopeSys' latest round of $1.1M is below the median round in Canada. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ScopeSys in Medical and Montréal
Companies Similar to ScopeSys
Telara Pharma designs a drug capable in the treatment and prevention of acute kidney injury.
Ceruvia Lifesciences is a developer of neuro transformational medicines for neurological diseases.
Good Protein is a food production company that produces plant-based functional superfood shakes and juices.
Experts know that the best answers cannot simply be looked up in a statute or found in a publisher’s online…
Blackletter is a law firm that provides venture financing, employment law, and corporate legal services
Aimer Development is involved in the creation of the inaugural artificial general intelligence specifically…
Thryv Therapeutics Inc., formerly known as LQT Therapeutics Inc., is a privately owned company located in…
Specific Biologics is creating a cutting-edge technology that includes a dual-cleaving nuclease capable of…
Solink is a security tool designed to actively prevent fraud by capturing and examining both video and…
Verdant Resource Partners is a private energy company focused on responsible oil and gas development and…
Wealthsimple is a fintech company that offers digital financial services to help investors grow and manage…
Juno is a company that explores battery and electric metals, providing mining services to discover critical…
ScopeSys Funding FAQs
What does ScopeSys do?
ScopeSys is a commercial-stage developer of disruptive technologies for single-molecule imaging.
How much funding has ScopeSys raised?
ScopeSys has raised $1.1M across 1 round on record. The most recent is a Seed of $1.1M announced in Aug 2026.
When did ScopeSys last raise funding?
ScopeSys' most recent funding round on record is a Seed of $1.1M, announced in Aug 2026.
Who has invested in ScopeSys?
Investors on record for ScopeSys include Xavaav Capital, WUTIF, VentureUs, Hextwo Capital, UBC Venture Funds.
Who is the CEO of ScopeSys?
Padma Kodukula is listed as Chief Executive Officer at ScopeSys.
Where is ScopeSys headquartered?
ScopeSys is based in Montréal, Canada.
How many employees does ScopeSys have?
ScopeSys is in the 11-50 employee band.
When was ScopeSys founded?
ScopeSys was founded in 2017.
About FundedIQ's ScopeSys Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ScopeSys is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.